---
title: "Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296134582.md"
description: "Mesoblast (NASDAQ:MESO) has completed patient dosing in its Phase 3 trial for rexlemestrocel-L, a cellular therapy for chronic low back pain. The study enrolled 350 participants to assess pain relief and opioid reduction. Targeting a $10 billion market, the treatment holds FDA Regenerative Medicine Advanced Therapy designation. Shares rose nearly 10% following the announcement, with final data expected in mid-2027."
datetime: "2026-08-17T17:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296134582.md)
  - [en](https://longbridge.com/en/news/296134582.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296134582.md)
generator: "portal-rs"
---

# Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

**Mesoblast Limited** (NASDAQ:MESO) stock is trading higher on Monday after the company concluded patient dosing for its crucial Phase 3 clinical trial evaluating rexlemestrocel-L.

The off-the-shelf cellular therapy aims to treat chronic low back pain linked to inflammatory degenerative disc disease, targeting a massive indication with a peak revenue potential exceeding $10 billion.

## High Demand Drives Trial Expansion

The MSB-DR004 study successfully randomized and administered treatments to 350 individuals, who received either a sham injection or a direct intra-discal dose of rexlemestrocel-L.

 **Read Also: Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy** 

Originally targeting 300 participants, the company expanded the cohort to 350 participants due to substantial enrollment interest from clinical investigators.

### Assessing Pain Relief And Opioid Reduction

The primary goal of the trial is to validate the lasting pain relief observed over a 12-month period following a single injection, a result previously noted in the MSB-DR003 study.

Armed with a larger participant base, the trial is well-equipped to demonstrate the therapeutic advantages over the control group.

Beyond primary pain reduction, researchers are tracking secondary outcomes such as functional improvements and enhanced quality of life.

The trial monitors the cessation of pain medications, particularly opioids. Discogenic back pain currently drives roughly half of all opioid prescriptions in the United States.

## Market Potential And Regulatory Pathway

Inflammation-driven chronic low back pain afflicts upwards of 7 million Americans. Capturing just a single-digit percentage of this market could yield immense financial returns for the global cellular medicine developer.

Rexlemestrocel-L, designed for patients suffering from the condition for under five years, already holds a Regenerative Medicine Advanced Therapy designation from the FDA.

This status paves the way for a priority review once a Biologics License Application is submitted. Final top-line data will be released in mid-2027 after the final patient finishes the one-year follow-up.

**MESO Price Action:** Mesoblast shares were up 9.84% to $17.13 at the time of publication on Monday, according to Benzinga Pro data.

 **Read Also: Gary Black Has ‘Low Interest’ in Tesla Stock at Current Price, Even With a Potential SpaceX Buyout** 

*Photo via Shutterstock*

### Related Stocks

- [MESO.US](https://longbridge.com/en/quote/MESO.US.md)
- [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md)

## Related News & Research

- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)
- [Dogwood Therapeutics highlights Halneuron Phase 2b data readout timeline for chemotherapy-induced neuropathic pain program](https://longbridge.com/en/news/298049944.md)
- [FibroBiologics wins new US patent for degenerative disc disease treatment using fibroblast conditioned media](https://longbridge.com/en/news/297652903.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**